PCSK5

Across TCGA pan-cancer cohorts, PCSK5 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated PCSK5 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PCSK5 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated PCSK5 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

UCEC, STAD, and BRCA are the cancer types where PCSK5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.925	0.591	.002	32	view →
STAD	DFS	Median	II,III,IV	0.876	0.340	.026	26	view →
BRCA	DFS	Median	All	0.694	0.904	<.001	24	view →
ESCA	DFS	Median	All	0.132	0.539	<.001	12	view →
SARC	DFS	Median	All	0.006	0.591	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	OS	Median	III,IV	0.202	0.688	.002	6	view →
SCLC	DFS	Median	II,III,IV	1.000	0.306	.027	6	view →
HNSC	OS	Median	IV	0.058	0.642	.001	6	view →
LIHC	OS	Median	All	0.025	0.775	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

PCSK5–UCEC (DFS)

Open the UCEC breakdown →